封面
市場調查報告書
商品編碼
1668455

2025 年神經調節全球市場報告

Neuromodulation Global Market Report 2025

出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年神經調節的市場規模將快速成長。到 2029 年,這一數字將成長到 117.9 億美元,年複合成長率(CAGR)為 11.3%。預測期內的成長歸因於設備的小型化、對老齡化社會的神經系統疾病的關注、精神病學應用的擴大、以患者為中心的方法以及全球醫療保健機會的增加。預測期內的關鍵趨勢包括人工智慧(AI)的整合、技術進步、非侵入性神經調節技術、閉合迴路神經調節系統、擴大適應症以及無線和穿戴式神經調節設備。

神經系統疾病的增加是神經調節市場成長的主要驅動力。這些疾病包括影響大腦、神經和脊髓的多種問題。神經調節干預為治療和調節多種神經系統疾病(包括阿茲海默症、帕金森氏症和癲癇)提供了一種有希望的方法。歐洲腦理事會2022年4月的報告顯示,全球整體已報告超過600種神經系統疾病和近300種精神疾病,有5000萬人患有阿茲海默症和其他失智症。癲癇影響全世界6500萬人,凸顯了神經系統疾病的嚴重影響。預計到 2050 年,歐洲患有失智症的人數將從 1050 萬大幅增加到 1870 萬,這表明神經調節可能在解決這一日益嚴重的健康問題中發揮關鍵作用。

預計未來幾年醫療保健支出的增加將推動神經調節市場的成長。醫療保健支出包括分配給醫療保健和相關活動的總資金,例如提供醫療服務、公共和私人醫療保險、衛生研究和公共衛生活動。增加的支出將用於支持神經系統疾病新治療方法和診斷方法的開發和採用,並為創新神經調節技術的研發、功效、安全性和針對性提供額外資金。例如,2022年11月,美國非營利組織加拿大衛生資訊研究所報告稱,2022年醫療保健費用將增加0.8%至3,310億美元,而2021年的增幅為7.6%。因此,醫療保健成本的增加正在推動神經調節市場的成長。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第 4 章 市場:宏觀經濟情景,包括利率、通膨、地緣政治、新冠疫情以及復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球神經調節PESTEL分析(政治、社會、技術、環境、法律因素、促進因素、限制因素)
  • 最終用途產業分析
  • 全球神經調節市場:成長率分析
  • 全球神經調節市場表現:規模與成長,2019 年至 2024 年
  • 全球神經調節市場預測:規模與成長,2024-2029 年,2034 年預測
  • 全球神經調節總目標市場 (TAM)

第6章 市場細分

  • 全球神經調節市場(按技術、性能和預測),2019-2024 年、2024-2029 年、2034 年
  • 內部神經調節
  • 外部神經調節(非侵入性)
  • 全球神經調節市場生醫材料、表現與預測,2019-2024 年、2024-2029 年、2034 年
  • 高分子生物材料
  • 金屬生醫材料
  • 陶瓷生醫材料
  • 全球神經調節市場:按應用、表現和預測,2019-2024 年、2024-2029 年、2034 年
  • 慢性疼痛
  • 尿失禁和大便失禁
  • 偏頭痛
  • 故障恢復綜合症
  • 帕金森氏症
  • 癲癇
  • 發抖
  • 憂鬱症
  • 其他用途
  • 全球神經調節市場:按最終用戶、績效和預測,2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 診所
  • 家庭醫療保健
  • 全球神經調節市場內部神經調節細分,按類型、實際和預測,2019-2024 年、2024-2029F、2034F
  • 嵌入式裝置
  • 椎管內藥物輸送系統
  • 全球神經調節市場,外部神經調節(非侵入性)細分,按類型、實際和預測,2019-2024 年、2024-2029F、2034F
  • 經顱磁刺激 (TMS)
  • 經顱直流電刺激(tDCS)
  • 經皮電刺激 (TENS)
  • 周邊神經刺激(PNS)

第7章 區域和國家分析

  • 全球神經調節市場:按地區、表現和預測,2019-2024 年、2024-2029 年、2034 年
  • 全球神經調節市場:按國家、表現和預測,2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章:中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第 17 章 德國市場

第 18 章 法國市場

第 19 章:義大利市場

第 20 章:西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第 25 章:加拿大市場

第26章 南美洲市場

第 27 章:巴西市場

第28章 中東市場

第 29 章:非洲市場

第 30 章競爭格局與公司概況

  • 神經調節市場:競爭格局
  • 神經調節市場:公司簡介
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Soterix Medical Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • Synapse Biomedical Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

  • Nevro Corp
  • Neuropace Inc.
  • LivaNova PLC
  • Neurosigma Inc.
  • Neuronetics Inc.
  • Bioness Inc.
  • Aleva Neurotherapeutics SA
  • Integer Holdings Corporation
  • ReShape Lifesciences Inc.
  • Inspire Medical Systems Inc.
  • Bioventus LLC
  • Saluda Medical Pty Ltd
  • Otolith Labs Inc.
  • Machine Medicine Inc.
  • Inbrain Neuroelectronics SAS

第 32 章 全球市場競爭基準化分析與儀表板

第33章 重大併購

第 34 章 近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

  • 2029 神經調節市場:提供新機會的國家
  • 2029 神經調節市場:提供新機會的細分市場
  • 神經調節市場 2029:成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第 36 章 附錄

簡介目錄
Product Code: r24363

Neuromodulation refers to the adjustment of nerve activity through electrical or pharmacological means, directly targeting specific areas. It's a reversible method employed to alleviate pain.

The primary technologies in neuromodulation include internal and external methods. Internal neuromodulation involves implanting an electrode near a targeted nerve and administering a low-voltage electric current. Biomaterials used encompass polymeric, metallic, and ceramic materials. These technologies are applied in treating various conditions such as chronic pain, urinary and fecal incontinence, migraine, failed back syndrome, Parkinson's disease, epilepsy, tremor, depression, and more. They find use across multiple settings including hospitals, clinics, and home healthcare environments.

The neuromodulation market research report is one of a series of new reports from The Business Research Company that provides neuromodulation market statistics, including the neuromodulation industry's global market size, regional shares, competitors with a neuromodulation market share, detailed neuromodulation market segments, market trends, and opportunities, and any further data you may need to thrive in the neuromodulation industry. This neuromodulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neuromodulation market size has grown rapidly in recent years. It will grow from$6.96 billion in 2024 to $7.68 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to rising prevalence of chronic disorders, clinical evidence and research, patient demand for non-invasive therapies, government initiatives and funding, expansion of indications, collaborations and partnerships

The neuromodulation market size is expected to see rapid growth in the next few years. It will grow to $11.79 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to miniaturization of devices, focus on neurological disorders in aging population, expanded applications in psychiatry, patient-centric approaches, global expansion of healthcare access. Major trends in the forecast period include integration of artificial intelligence (ai), advancements in technology, non-invasive neuromodulation techniques, closed-loop neuromodulation systems, expansion of indications, wireless and wearable neuromodulation devices.

The increasing prevalence of neurological disorders stands as a significant driver for the growth of the neuromodulation market. These disorders encompass a wide range of issues affecting the brain, nerves, and spinal cord. Neuromodulation interventions offer promising avenues for managing and regulating various neurological conditions, including Alzheimer's, Parkinson's, and epilepsy. Reports from the European Brain Council in April 2022 highlighted over 600 neurological diseases and nearly 300 psychiatric conditions globally, with 50 million individuals affected by Alzheimer's and other dementias. Epilepsy, affecting 65 million people worldwide, underscores the substantial impact of neurological disorders. Projections indicate a substantial rise in dementia cases in Europe, from 10.5 million to 18.7 million by 2050, signifying the pivotal role of neuromodulation in addressing these escalating health concerns.

Increasing healthcare expenditures are projected to drive the growth of the neuromodulation market in the coming years. Healthcare expenditure encompasses the total funds allocated for health care and related activities, including health services provision, public and private health insurance, health research, and public health initiatives. Rising expenditures support the development and adoption of new therapies and diagnostic methods for neurological disorders, and they also provide additional funding for research into innovative neuromodulation technologies, enhancing their efficacy, safety, and targeting capabilities. For example, in November 2022, the Canadian Institute for Health Information, a not-for-profit organization based in the U.S., reported that healthcare expenditure increased by 0.8% to reach $331 billion in 2022, compared to 7.6% in 2021. Thus, the rising healthcare expenditure is fueling the growth of the neuromodulation market.

Technological advancements are a significant trend gaining traction in the neuromodulation market. Leading companies in this sector are concentrating on developing innovative technological solutions to enhance their market position. For instance, in January 2024, GrayMatters Health, an Israel-based firm focused on digital self-neuromodulation therapies, introduced a new FDA-cleared self-neuromodulation therapy for PTSD called Prism. This cutting-edge device integrates an EEG cap with software to assist patients in learning to manage their emotional responses through neurofeedback. The technology aims to complement traditional psychotherapy and pharmacotherapy by equipping patients with tools to actively manage their symptoms. Additionally, in December 2022, Abbott Laboratories, a U.S.-based medical devices and healthcare company, unveiled the Eterna spinal cord stimulation (SCS) system, which is the smallest implantable, rechargeable spinal cord stimulator available. Eterna SCS utilizes Abbott's patented low-dose BurstDR stimulation, the only SCS waveform innovation backed by the highest level of clinical evidence (1A evidence), demonstrating a 23% greater pain relief compared to conventional waveform technology.

Major players in the neuromodulation market are focusing on introducing next-generation devices with advanced features, such as the implantable pulse generator (IPG), to gain a competitive edge. For example, CVRx's November 2022 launch of the Barostim Neo2 IPG, an upgraded version of its neuromodulation device for heart failure treatment, exemplifies this pursuit. With improved efficiency, reduced size, and enhanced design facilitating easier implantation, the Barostim Neo2 retains the clinically proven Barostim therapy, emphasizing the drive towards patient-friendly, durable, and efficient solutions in neuromodulation.

In March 2022, Electromedical Products International Inc (EPI), a prominent US-based medical device manufacturer, completed the acquisition of Pulvinar Neuro LLC for an undisclosed sum. This strategic acquisition empowers EPI to further its progress in advancing patented technologies, notably transcranial alternating current stimulation (tACS), enhancing personalized feedback stimulation, and expanding its cloud-enabled digital therapeutics for psychiatric and neurological conditions. Pulvinar Neuro, a US-based neurotechnology company, specializes in leveraging cutting-edge technologies to support neuroscience research, aligning seamlessly with EPI's objectives in advancing medical innovation in this domain.

Major companies operating in the neuromodulation market include Abbott Laboratories, Soterix Medical Inc., Boston Scientific Corporation, Medtronic plc, Synapse Biomedical Inc., Nevro Corp, Neuropace Inc., LivaNova PLC, Neurosigma Inc., Neuronetics Inc., Bioness Inc., Aleva Neurotherapeutics S.A., Integer Holdings Corporation, ReShape Lifesciences Inc., Inspire Medical Systems Inc., Bioventus LLC, Saluda Medical Pty Ltd, Otolith Labs Inc., Machine Medicine Inc., Inbrain Neuroelectronics SAS, Pixium Vision SA, Neuromod Devices Limited, Cognito Therapeutics Inc., PathMaker Neurosystems Inc., Dignify Therapeutics Inc., Neuronoff ApS, Neuros Medical Inc., Fisher & Paykel Healthcare Corporation Limited, Koninklijke Philips N.V., Magic Leap Inc., Omron Corporation

North America was the largest region in the neuromodulation market in 2024. The regions covered in the neuromodulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the neuromodulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The neuromodulation market includes revenues earned by entities through sacral nerve stimulation for pelvic disorders and incontinence, deep brain stimulation (DBS) treatment for Parkinson's disease, and spinal cord stimulation for ischemic disorders (angina, peripheral vascular disease). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuromodulation Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuromodulation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuromodulation ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neuromodulation market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Technology: Internal Neuromodulation; External Neuromodulation (Non-invasive)
  • 2) By Biomaterial: Polymeric Biomaterial; Metallic Biomaterial; Ceramic Biomaterial
  • 3) By Application: Chronic Pain; Urinary And Fecal Incontinence; Migraine; Failed Back Syndrome; Parkinson Disease; Epilepsy; Tremor; Depression; Other Applications
  • 4) By End-User: Hospitals; Clinics; Home Healthcare
  • Subsegments:
  • 1) By Internal Neuromodulation: Implantable Devices; Intrathecal Drug Delivery Systems
  • 2) By External Neuromodulation (Non-invasive): Transcranial Magnetic Stimulation (TMS); Transcranial Direct Current Stimulation (tDCS); Transcutaneous Electrical Nerve Stimulation (TENS); Peripheral Nerve Stimulation (PNS)
  • Companies Mentioned: Abbott Laboratories; Soterix Medical Inc.; Boston Scientific Corporation; Medtronic plc; Synapse Biomedical Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neuromodulation Market Characteristics

3. Neuromodulation Market Trends And Strategies

4. Neuromodulation Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Neuromodulation Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Neuromodulation PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Neuromodulation Market Growth Rate Analysis
  • 5.4. Global Neuromodulation Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Neuromodulation Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Neuromodulation Total Addressable Market (TAM)

6. Neuromodulation Market Segmentation

  • 6.1. Global Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Internal Neuromodulation
  • External Neuromodulation (Non-invasive)
  • 6.2. Global Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymeric Biomaterial
  • Metallic Biomaterial
  • Ceramic Biomaterial
  • 6.3. Global Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chronic Pain
  • Urinary And Fecal Incontinence
  • Migraine
  • Failed Back Syndrome
  • Parkinson Disease
  • Epilepsy
  • Tremor
  • Depression
  • Other Applications
  • 6.4. Global Neuromodulation Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinics
  • Home Healthcare
  • 6.5. Global Neuromodulation Market, Sub-Segmentation Of Internal Neuromodulation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Implantable Devices
  • Intrathecal Drug Delivery Systems
  • 6.6. Global Neuromodulation Market, Sub-Segmentation Of External Neuromodulation (Non-invasive), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Transcranial Magnetic Stimulation (TMS)
  • Transcranial Direct Current Stimulation (tDCS)
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Peripheral Nerve Stimulation (PNS)

7. Neuromodulation Market Regional And Country Analysis

  • 7.1. Global Neuromodulation Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Neuromodulation Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neuromodulation Market

  • 8.1. Asia-Pacific Neuromodulation Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neuromodulation Market

  • 9.1. China Neuromodulation Market Overview
  • 9.2. China Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neuromodulation Market

  • 10.1. India Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neuromodulation Market

  • 11.1. Japan Neuromodulation Market Overview
  • 11.2. Japan Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neuromodulation Market

  • 12.1. Australia Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neuromodulation Market

  • 13.1. Indonesia Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neuromodulation Market

  • 14.1. South Korea Neuromodulation Market Overview
  • 14.2. South Korea Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neuromodulation Market

  • 15.1. Western Europe Neuromodulation Market Overview
  • 15.2. Western Europe Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neuromodulation Market

  • 16.1. UK Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neuromodulation Market

  • 17.1. Germany Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neuromodulation Market

  • 18.1. France Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neuromodulation Market

  • 19.1. Italy Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neuromodulation Market

  • 20.1. Spain Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neuromodulation Market

  • 21.1. Eastern Europe Neuromodulation Market Overview
  • 21.2. Eastern Europe Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neuromodulation Market

  • 22.1. Russia Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neuromodulation Market

  • 23.1. North America Neuromodulation Market Overview
  • 23.2. North America Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neuromodulation Market

  • 24.1. USA Neuromodulation Market Overview
  • 24.2. USA Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neuromodulation Market

  • 25.1. Canada Neuromodulation Market Overview
  • 25.2. Canada Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neuromodulation Market

  • 26.1. South America Neuromodulation Market Overview
  • 26.2. South America Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neuromodulation Market

  • 27.1. Brazil Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neuromodulation Market

  • 28.1. Middle East Neuromodulation Market Overview
  • 28.2. Middle East Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neuromodulation Market

  • 29.1. Africa Neuromodulation Market Overview
  • 29.2. Africa Neuromodulation Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Neuromodulation Market, Segmentation By Biomaterial, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Neuromodulation Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neuromodulation Market Competitive Landscape And Company Profiles

  • 30.1. Neuromodulation Market Competitive Landscape
  • 30.2. Neuromodulation Market Company Profiles
    • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Soterix Medical Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Synapse Biomedical Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Neuromodulation Market Other Major And Innovative Companies

  • 31.1. Nevro Corp
  • 31.2. Neuropace Inc.
  • 31.3. LivaNova PLC
  • 31.4. Neurosigma Inc.
  • 31.5. Neuronetics Inc.
  • 31.6. Bioness Inc.
  • 31.7. Aleva Neurotherapeutics S.A.
  • 31.8. Integer Holdings Corporation
  • 31.9. ReShape Lifesciences Inc.
  • 31.10. Inspire Medical Systems Inc.
  • 31.11. Bioventus LLC
  • 31.12. Saluda Medical Pty Ltd
  • 31.13. Otolith Labs Inc.
  • 31.14. Machine Medicine Inc.
  • 31.15. Inbrain Neuroelectronics SAS

32. Global Neuromodulation Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuromodulation Market

34. Recent Developments In The Neuromodulation Market

35. Neuromodulation Market High Potential Countries, Segments and Strategies

  • 35.1 Neuromodulation Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Neuromodulation Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Neuromodulation Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer